Methods of monitoring inflammatory bowel diseases
Inventors
Colombel, Jean-Frederic • Ferrara, James • Levine, John E. • Ozbek, Umut • UNGARO, Ryan
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present application discloses diagnostic methods and kits for detecting disease activity in a subject having an inflammatory bowel disease, such as Crohn's disease. Methods of treating endoscopically active gastrointestinal disease, as well as methods of determining effectiveness of a treatment for endoscopically active gastrointestinal disease in a subject, are also disclosed.
Core Innovation
The invention relates to a method for detecting Crohn's disease in a human subject by detecting expression levels of regenerating islet-derived protein 3 alpha (REG3α) and C-reactive protein (CRP) in a biological sample comprising at least one of a serum sample or a whole blood sample. The method generates a combined REG3α/CRP index score by applying a statistical algorithm to the expression levels of REG3α and CRP, and the subject is determined to have or be likely to have Crohn's disease based on the combined REG3α/CRP index score being higher than an optimal classification threshold.
The approach supports use of logistic/statistical algorithms to produce a probability (p) via a logit expression based on log10-transformed REG3α and CRP expression levels. Classification uses an optimal classification threshold to distinguish Crohn's disease determination.
The invention further includes administering to the human subject a therapeutic agent under conditions effective to treat Crohn's disease after determining that the subject has or is likely to have Crohn's disease based on the combined REG3α/CRP index score. In addition, the invention provides a method of determining effectiveness of a treatment of Crohn's disease in a human subject by detecting expression levels of REG3α and CRP in a first biological sample before treatment, generating a first combined REG3α/CRP index score, detecting expression levels again in a second biological sample after treatment, generating a second combined REG3α/CRP index score, and comparing the second combined REG3α/CRP index score to the first combined REG3α/CRP index score to determine effectiveness.
Claims Coverage
Two independent claims are provided. Both claims center on REG3α and CRP expression in biological samples, statistical transformation into a combined REG3α/CRP index score, and decision making based on an optimal classification threshold or comparison of index scores to determine effectiveness. Across the claim set, the inventive features include generation of a combined index score, use of probability-based logistic/statistical algorithms, threshold-based classification, and treatment effectiveness determination via pre- and post-treatment score comparison.
REG3α/CRP detection and combined index score generation for Crohn's disease detection
Detecting expression levels of regenerating islet-derived protein 3 alpha (REG3α) and C-reactive protein (CRP) in a biological sample comprising at least one of a serum sample or a whole blood sample; applying a statistical algorithm to said expression levels of REG3α and CRP to generate a combined REG3α/CRP index score; and determining that the human subject has or is likely to have Crohn's disease based on the combined REG3α/CRP index score being higher than an optimal classification threshold.
Administration of a therapeutic agent after classification based on combined REG3α/CRP index score
Administering to the human subject a therapeutic agent under conditions effective to treat Crohn's disease in the human subject, where the therapeutic agent administration follows from the determining that the subject has or is likely to have Crohn's disease based on the combined REG3α/CRP index score being higher than an optimal classification threshold.
Pre- and post-treatment REG3α/CRP index score comparison to determine treatment effectiveness
Detecting expression levels of regenerating islet-derived protein 3 alpha (REG3α) and C-reactive protein (CRP) in a first biological sample before the human subject receives the treatment; applying a statistical algorithm to generate a first combined REG3α/CRP index score; detecting expression levels of REG3α and CRP in a second biological sample after treatment; applying a statistical algorithm to generate a second combined REG3α/CRP index score; and comparing the second combined REG3α/CRP index score to the first combined REG3α/CRP index score to determine effectiveness of the treatment.
The claims coverage focuses on determining Crohn's disease status and treatment effectiveness using expression levels of REG3α and CRP in biological samples. A combined REG3α/CRP index score is generated by a statistical algorithm, with Crohn's disease classification based on an optimal classification threshold, and treatment effectiveness determined by comparing combined index scores obtained before and after treatment.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?